Page URL: https://www.bionews.org.uk/page_94143

Stroke patients improve after stem cell treatment

3 June 2013
Appeared in BioNews 707

Five stroke patients in a stem cell therapy trial have shown improvements in their symptoms, according to interim results.

In the first trial to use stem cell therapy in stroke patients, five of the nine people treated have shown unexpected partial recovery from their disabilities. 'We've seen people who now have the ability to move their fingers where they have had several years of complete paralysis', lead researcher Professor Keith Muir from the University of Glasgow told the BBC.

The patients, treated at Glasgow's Southern General Hospital, had previously shown no signs of spontaneous improvement following their strokes. 80-year-old Frank Marsh, told the BBC: 'I can now grip things that I couldn't grip before, like the hand rails at the swimming baths'.

Caused by a lack of blood to a part of the brain, stroke can cause severe, lasting damage. Trial participants received an injection of neural stem cells directly into the damaged area of their brains. As stem cells retain the able to multiply and develop into a variety of mature cell types, it is hoped they could limit or reverse any damage to the brain cells of stroke victims.

Announced at the recent European Stroke Conference, researchers revealed the interim findings of the ongoing Pilot Investigation of Stem Cells in Stroke (PISCES) trial. As a phase I clinical trial, this study is designed to assess the safety of the procedure on a small number of people. 'We remain pleased and encouraged by the data emerging from the PISCES study. The data to date identify no safety issues with the [stem cell] treatment', said Professor Muir.

While encouraging, the success of these five patients is not enough to prove that the therapy is causing the partial recoveries. Only larger trials with more patients and correct controls can establish whether the treatment is genuinely working, and that improvements are not just due to the placebo effect.

The neural stem cell line used was developed by ReNeuron – who sponsored the trial – and had previously been shown to improve symptoms in rats. There is some opposition from anti-abortion campaigners to the use of these cells, as they were originally derived from a human fetus sample.

The team plan to seek approval for a phase II trial when they submit the updated findings of the trial in early July, and hope to begin recruitment for a second trial shortly after.

SOURCES & REFERENCES
Encouraging data from stem cell trial in stroke patients as plans for Phase II progress
University of Glasgow (press release) |  27 May 2013
Stem cell stroke treatment trial results 'show promise'
NHS Choices |  28 May 2013
Stroke patients see signs of recovery in stem-cell trial
BBC News |  27 May 2013
Stroke victims show signs of recovery following pioneering stem cell therapy
The Independent |  27 May 2013
RELATED ARTICLES FROM THE BIONEWS ARCHIVE
18 August 2014 - by Dr Barbara Kramarz 
Five stroke patients have begun to recover after being treated with their own stem cells, and have reported no side effects six months after treatment...
29 July 2013 - by Lanay Tierney 
UK biotech company ReNeuron is to relocate to Wales after securing £7.8m in grants and £5m equity investment from the Welsh government...
20 May 2013 - by Dr Rosie Gilchrist 
Embryonic stem cells have been created from human skin cells for the first time by US scientists using a cloning technique...
7 May 2013 - by David O'Rourke 
A toddler has become the youngest person to receive a bioengineered organ, receiving a life-saving windpipe transplant made from her own stem cells...
29 April 2013 - by Siobhan Chan 
Stem cell therapy has improved memory and learning in brain-damaged mice, according to a study in Nature Biotechnology...
22 April 2013 - by Dr Anna Cauldwell 
Skin cells have been directly converted into the types of cells destroyed in patients with myelin disorders like multiple sclerosis and cerebral palsy in a pair of studies on mice...
HAVE YOUR SAY
Log in to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions


Syndicate this story - click here to enquire about using this story.